|
|
| Fukumasu,H.; Cordeiro,Y.G.; Rochetti,A.L.; Barra,C.N.; Sámora,T.S.; Strefezzi,R.F.; Dagli,M.L.Z.. |
| Nuclear receptor subfamily 1, group I, member 3 (NR1I3) is reported to be a possible novel therapeutic target for some cancers, including lung, brain and hematopoietic tumors. Here, we characterized expression of NR1I3 in a mouse model of lung carcinogenesis induced by 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone (NNK), the most potent tobacco carcinogen. Lung tumors were collected from mice treated with NNK (400 mg/kg) and euthanized after 52 weeks. Benign and malignant lesions were formalin-fixed and paraffin-embedded for histology and immunohistochemistry, with samples snap-frozen for mRNA analysis. Immunohistochemically, we found that most macrophages and type I and II pneumocytes expressed NR1I3, whereas fibroblasts and endothelial cells were... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: NR1I3; CAR; NNK; Cyclin D1; Lung carcinogenesis. |
| Ano: 2015 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000300240 |
| |
